Prognostic Implications of Sokal, Hasford, and EUTOS scores on Complete Hematologic and Early Molecular Responses in Newly Diagnosed Chronic Myeloid Leukemia Patients: A Prospective Cohort Study

Sokal, Hasford, and EUTOS prognostic scoring systems are widely used for chronic myeloid leukemia (CML) patients. However, whether one of these scoring systems was better predicting therapeutic responses among patients treated with tyrosine kinase inhibitor (TKI) remains elusive. This study was aimed to assess the correlation of each prognostic score with therapeutic responses—complete hematologic response (CHR) and early molecular response (EMR) after treated with Imatinib mesylate. 40 CML patients with the mean of age of 40 ± 11 years from Indonesian population were followed-up prospectively. The CHR at 3 months was seen in 40.7%, 18.6%, and 40.7% in Sokal low-, intermediate- and high-risk groups respectively, 26.0%, 40.7%, and 33.3% in Hasford low-, intermediate- and high-risk groups respectively, 100% and 0% EUTOS low- and high-risk groups respectively. The EMR at 3 months was seen in 41.7%, 16.6%, and 41.7% in Sokal low-, intermediate- and high-risk groups respectively, 29.2%, 37.5% and 33.3% in Hasford low-, intermediate- and high-risk groups respectively, 100% and 0% in EUTOS low- and high-risk groups respectively. However, none of these scoring systems predicted CHR and EMR at 3 months among CML patients treated with Imatinib.